Physician profile
James D Judd
NPI 1619961893
$550.16
in general payments reported to CMS, 2019-2025
15 companies · $17.58 in 2025
The $17.58 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $56.31 · 2021: $84.09 · 2022: $101 · 2023: $50.30 · 2025: $17.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $96.61 | 2021-2022 | |
| Novo Nordisk INC | $93.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $61.37 | 2019 | |
| Abbott Laboratories | $40.71 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $31.02 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $30.98 | 2019-2022 | |
| Pfizer INC. | $28.33 | 2019-2022 | |
| Lilly USA, LLC | $27.44 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.80 | 2023 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $22.51 | 2019 | |
| Allergan, INC. | $21.76 | 2019 | |
| Vertos Medical, INC. | $20.55 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.58 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $17.27 | 2019 | |
| Glaxosmithkline, LLC. | $13.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Judd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.